Milacemide: A Placebo‐Controlled Study in Senile Dementia of the Alzheimer Type

Maurice W Dysken, Joseph Mendels, Peter LeWitt, Barry Reisberg, Nunzio Pomara, James Wood, Stacy Skare, J. Daniel Fakouhi, Robert L. Herting

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Milacemide, a MAO‐B inhibitor that is also a prodrug for glycine, was tested as a treatment for senile dementia of the Alzheimer type (SDAT) because of its potential for enhancing cognition in animal models of impaired learning and memory. Double‐blind, placebo‐controlled, randomized clinical trial. Sixteen study sites, both university‐affiliated and private. A total of 228 outpatients (116 men and 112 women) with SDAT, ranging in age from 49–93 years. Intervention: 1200 mg/day milacemide treatment for 1 month (113 patients received milacemide, and 115 patients received placebo). Alzheimer's Disease Assessment Scale and the Mini‐Mental State Examination. Milacemide‐treated SDAT patients did not show significant improvement in any of the outcome measures used. Significant elevations in liver enzymes in four subjects were of sufficient magnitude to necessitate withdrawal from the study. Milacemide does not appear to be an effective treatment in enhanci g cognition in SDAT patients.

Original languageEnglish (US)
Pages (from-to)503-506
Number of pages4
JournalJournal of the American Geriatrics Society
Issue number5
StatePublished - May 1992

Fingerprint Dive into the research topics of 'Milacemide: A Placebo‐Controlled Study in Senile Dementia of the Alzheimer Type'. Together they form a unique fingerprint.

Cite this